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OncologyAbstract Background: Smoking cessation after a cancer diagnosis is associated with
improved overall survival. Few studies have reported oncologists’ cessation practice patterns,
but differences between the curative and palliative settings have not been described. We aimed
to study the oncologist’s perceptions on patients’ tobacco use, current practices and barriers to
providing smoking cessation support, while distinguishing between treatment with curative
(C) and palliative (P) intent.
Methods: In 2019, an online 34-item survey was sent to approximately 6235 oncologists from
16 European countries. Responses were descriptively reported and compared by treatment
setting.
Results: Responses from 544 oncologists were included. Oncologists appeared to favour ad-
dressing tobacco in the curative setting more than in the palliative setting. Oncologists believe
that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation sup-
port should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C:
93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)
e39% (C) routinely discuss medication options, and only 18% (P)e31% (C) provide cessation
support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking
affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative
settings (p < 0.001), but dominant barriers of time, resources, education and patient resistance
were similar between settings.
Conclusion: Oncologists appear to favour addressing tobacco use more in the curative setting;
however, they discuss medication options and/or provide cessation support in a minority of
cases. All patients who report current smoking should have access to evidence-based smoking
cessation support, also patients treated with palliative intent given their increasing survival.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Despite the great progress made in supportive care for
people with cancer, smoking cessation treatments remain
an often-neglected element of cancer care. Smoking by
cancer patients and survivors causes adverse cancer
treatment outcomes and poor quality of life with a me-
dian 50% increased risk of overall mortality and 60%
increased risk of cancer-related mortality across cancer
diagnoses and treatments [1]. In addition, the effects of
continued smoking can result in significant additional
cancer-related treatment costs [2]. Smoking cessation
after a cancer diagnosis can improve survival [3], and
improve outcomes for nonecancer-related health effects
that may have a more significant effect on mortality than
cancer [4]. Major organisations including the European
Society for Medical Oncology (ESMO), American So-
ciety of Clinical Oncology (ASCO), American Associa-
tion for Cancer Research, National Comprehensive
Cancer Network, International Association for the
Study of Lung Cancer (IASLC), World Health Organi-
sation and others advocate for smoking cessation as a
standard part of cancer care [5e12]. However, approxi-
mately two-thirds of cancer patients who smoke at
diagnosis continue to smoke during follow-up [13].
Evidence-based approaches to increase smoking
cessation consist of providing counselling and medica-
tions [14]. Before the landmark 2014 Surgeon General’s
Report concluding that smoking was a causal factor forpoor cancer treatment outcomes [1], large surveys of
oncologists demonstrated that while most oncologists
asked about tobacco use and advised patients to quit,
few offered assistance with quitting [15,16]. There have
been considerable efforts to raise awareness of the need
to provide smoking cessation as a standard part of
cancer care, but there have only been few contemporary
surveys of practice patterns to evaluate if improvement
has occurred. In addition, no previous surveys have
evaluated differences in patterns between the curative
and palliative settings. The purpose of this study is to
evaluate current practice patterns of oncologists by
reporting (1) their perceptions on tobacco use after
diagnosis, (2) current practices of tobacco use assessment
including provision of cessation support and (3) poten-
tial barriers to facilitating cessation supportdwhile dis-
tinguishing between the curative and palliative settings.
2. Methods
2.1. Study population
Target respondents included clinical oncologists (i.e.
medical oncologists and radiation oncologists) prac-
ticing in Europe. In total, 24 national societies for
medical or clinical oncologydall partners of
ESMOdwere invited to participate in this international
survey study (Supplement S1). On individual board
approval, the societies distributed the survey among
Table 1
Respondent characteristics (n Z 544).
Characteristic No. %




Sex (n Z 453a)
Male 185 41
Female 268 59
Degree (n Z 453a)
MD 283 63
MD, PhD 168 37
Other 2 1
Primary area of clinical
practice (n Z 449a)
Medical oncology 406 90
Radiation oncology 29 7
Clinical oncology 11 2
Thoracic oncology 3 1
Work-setting (n Z 453a)
University, academic 227 50
Hospital-based, non-academic 199 44
Other 27 6
















United Kingdom 72 13
Other 5 1
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Table 1 (continued )
Characteristic No. %
Respondent’s tobacco
use history (n Z 453a)
Current smoker 22 5
Ever smoker 79 17
Never smoker 352 78
a 17% missing, and descriptive statistics of complete cases are
presented.
J.W.G. Derksen et al. / European Journal of Cancer 138 (2020) 99e108 101their members and most local coordinators sent two
reminders after the initial invitation to complete the
survey. The Medical Research Ethics Committee
(MREC) of the University Medical Center Utrecht
confirmed that the Medical Research Involving Human
Subjects Act (WMO) does not apply, and MREC
approval is not required under the WMO (reference
WAG/mb/19/013713).
2.2. Survey
An online 34-item survey was developed based on the
2013 ASCO survey [15] to assess European practice
patterns in clinical oncology and perceptions regarding
smoking cessation after a cancer diagnosis. The survey
contained questions asking about respondent charac-
teristics, the oncologist’s perceptions of tobacco use in
patients with cancer, the oncologist’s interactions with
cancer patients, and potential barriers to smoking
cessation support (Supplement S2). Respondents were
asked about practice patterns and perceptions in both
the curative and palliative settings. Except for the
respondent’s demographics, most questions could be
answered on a five-level Likert scale ranging from al-
ways to never, or from strongly agree to strongly
disagree. The survey was distributed between 19th
September 2019 and 20th December 2019.
2.3. Data analysis
Responses to the survey are presented using descriptive
statistics, and compared by treatment setting using the
non-parametric ManneWhitney U test. Statistical ana-
lyses were performed using SPSS (version 25.0, IBM
Corp, Armonk, NY). To determine the respondent’s
smoking status, currently smoking every day or some
days per week was classified as being a current smoker,
currently no smoking but having smoked more than 100
in a lifetime was classified as being an ever smoker, and
never smoking in a lifetime or no current smoking but
having smoked less than 100 in a lifetime was classified
as being a never smoker.
3. Results
A total of 6235 members of participating medical or
clinical oncology societies from Belgium, Denmark,
J.W.G. Derksen et al. / European Journal of Cancer 138 (2020) 99e108102Estonia, Finland, Germany, Greece, Ireland, Lithuania,
Luxembourg, The Netherlands, Poland, Serbia, Spain,
Sweden, Switzerland and the United Kingdom (UK)
were invited to participate. Of all invited members, 568
(~9.1%) completed the survey for this study, with vary-
ing response rates by country ranging from 2% to 44%.
After excluding respondents with another profession (18
surgeons and 6 miscellaneous), a total of 544 re-
spondents (~8.7%) were included in this analysis.3.1. Respondent characteristics
Table 1 shows characteristics of the 544 survey re-
spondents. Most respondents were older than 40
years (73%), and practicing as medical oncologist (90%).
Furthermore, 41% of respondents were men, 37% had
an MD with a doctorate degree and 50% reported to be
working in a university or academic setting. Breast,
gastrointestinal and lung tumours were the three most
frequently seen primary tumour types of respondents
with respectively 49%, 46% and 39%. The majority of
respondents reported to spend more than half of their
time on patient care (90%). Regarding smoking behav-
iour, 5% of the clinical oncologists reported to currently
smoke, and 17% were classified as ever smoker.3.2. Perceptions on tobacco and cancer
Responses on questions regarding perceptions towards
tobacco use in patients with cancer are shown in Table
2. Oncologists strongly believe that tobacco use nega-
tively impacts treatment outcomes, in both the curative
(94%) and palliative settings (74%). Subsequently, 95%
of the respondents agreed that smoking cessation
should be a standard part of curative cancer treatment,
and 63% agreed that it should be standard in the
palliative setting as well. Interestingly, 52% reported to
not have adequate training in smoking cessation in-
terventions, and 73% indicated that more training in
tobacco assessment and cessation interventions is
needed. This is especially relevant as 42% found that the
treating oncologist would be an appropriate provider of
cessation support. The two other most frequently sug-
gested providers were primary care physicians (58%)
and clinical support staff such as nurses (56%). A
stratification by country showed that primary care
physicians were less often (<50%) suggested in Ger-
many, Greece, Luxemburg, Serbia and Sweden, and
more often (>75%) in Spain, Switzerland and the UK.
The most commonly reported methods in the re-
spondents’ hospital to support patients in tobacco
cessation are face-to-face counselling (37%), and the
provision of information materials such as pamphlets
(29%), but 23% of the respondents reported no
knowledge of a dedicated smoking cessation program
available in their centre.3.3. Interactions with the patient
Table 3 shows the oncologists’ practices and commu-
nication with the patient. The vast majority of re-
spondents reported to always or most of the time ask
patients if they smoke tobacco products, in both the
curative (93%) and palliative (78%) settings. Asking
about using specific tobacco products was less
frequently reported as 57% of oncologists indicated to
ask for cigar, pipe, snuff use in the curative setting and
48% in the palliative setting, while the use of electronic
cigarettes or devices was reported to be asked always
or most of the time by 39% of the oncologists in the
curative setting and by 33% in the palliative setting.
When asking patients about tobacco use, most oncol-
ogists do not use a structured method for the assess-
ment (rarely or never by 69% in the curative setting
and 71% in the palliative setting). Although oncologists
indicated that they do ask smokers if they want to quit
smoking (always or most of the time by 75% in the
curative setting and 50% in the palliative setting) and
also advise smokers to quit (88% in the curative setting
and 54% in the palliative setting), only 39% reported to
discuss medication options always or most of the time
with curative patients, and 24% with palliative patients.
Overall, 69% of the respondents reported to discuss
tobacco use and cessation options equally in patients
with tobacco-related and nonetobacco-related
cancers in the curative setting, and 58% in the palliative
setting.
3.4. Barriers for interventions
Oncologists agreed or strongly agreed that the
perceived inability to get patients to quit (69% in the
curative setting and 61% in the palliative setting), the
patient’s resistance (69% in the curative setting and
70% in the palliative setting), the lack of time for
counselling (59% in the curative setting and 54% in the
palliative setting) and a lack of training in cessation
interventions (65% in the curative setting and 61% in
the palliative setting) are barriers to facilitate smoking
cessation interventions (Table 4). In contrast, very few
respondents agreed or strongly agreed that smoking
cessation after diagnosis is a waste of time (3% in the
curative setting and 14% in the palliative setting,
p < 0.001). The oncologist’s own hesitation and ‘not
feeling comfortable taking something away patients
might enjoy doing’ are more present in the palliative
setting since 43% agreed or strongly agreed to this
statement, as compared with 13% in the curative setting
(p < 0.001). When stratified for tobacco use history,
oncologists that are current or former smokers do not
differ from never smokers in terms of their own hesi-
tation as a barrier to provide cessation support, neither
in the curative setting (p Z 0.53) nor in the palliative
setting (p Z 0.63).
Table 2
Oncologist’s perceptions of tobacco use in patients with cancer.







No. (%) No. (%) No. (%) No. (%) No. (%) C versus P
Current smoking or tobacco use impacts treatment
outcomes in cancer patients
C 286 (60%) 164 (34%) 23 (5%) 4 (1%) 2 (<1%) <0.001
P 135 (28%) 220 (46%) 96 (20%) 25 (5%) 3 (1%)
Smoking/tobacco cessation should be a standard part
of cancer treatment interventions
C 308 (64%) 147 (31%) 18 (4%) 5 (1%) 1 (<1%) <0.001
P 123 (26%) 179 (37%) 112 (23%) 62 (13%) 3 (1%)
I have had adequate training in smoking/tobacco
cessation interventions
e 19 (4%) 90 (19%) 119 (25%) 209 (44%) 42 (9%) e
Clinicians need more training in smoking/tobacco
assessment and cessation interventions
e 120 (25%) 231 (48%) 94 (20%) 32 (7%) 2 (<1%) e
Question Selected
No. (%)
Which of the following providers do you think is appropriate to provide cessation support for cancer
patients on a regular basis (more answers were possible)
A. Primary care physician 315 (58%)
B. MD level provider, other than primary care physician 75 (14%)
C. Mid-level clinician such as a nurse practitioner or physician assistant 202 (37%)
D. Clinical support staff within the clinic such as a nurse, psychologist, or social worker 306 (56%)
E. The treating oncologist 227 (42%)
F. I would not use any of the above resources 9 (2%)
G. Other 29 (5%)
What type of dedicated smoking/tobacco cessation program does your Cancer Center or Clinic have
available for your cancer patients (more answers were possible)
A. A tobacco cessation clinic/specialist that provides face-to-face counselling 199 (37%)
B. A tobacco cessation specialist who provides telephone based counselling 47 (9%)
C. A tobacco cessation clinic/specialist that provides pharmacotherapy 92 (17%)
D. Provision of tobacco cessation materials, such as pamphlets or a DVD 159 (29%)
E. None to my knowledge 124 (23%)
F. I don’t know 55 (10%)
G. Other 20 (4%)
C Z curative, P Z palliative.
a 12% missing, and descriptive statistics of complete cases are presented.
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Among European oncologists who responded to the
online survey on smoking cessation in patients with
cancer, most reported to believe that tobacco use
negatively impacts treatment outcomes, and that
smoking cessation interventions should be a part of the
multidisciplinary treatment. Most oncologists ask pa-
tients for tobacco use and advise those who use tobacco
to quit, in both the curative and palliative settings, and
with similar frequency for both patients with tobacco-
related and nonetobacco-related cancers. Use of specific
tobacco products or electronic cigarettes is less
frequently interrogated. Barriers to provide cessation
support were conceived rather equally between the
curative and palliative settings, with a lack in training,
the perception of inability to get patients to quit, patient
resistance, and a lack of time being the most frequently
reported. Oncologists appeared to report higher rates of
addressing tobacco in the curative setting as compared
with the palliative setting, but except for the oncologist’s
own hesitations to take away a pleasurable habit(equally present in currently/former smoking oncolo-
gists versus non-smoking oncologists) and disbelief in an
effect on outcomes, barriers were remarkably similar
between the curative and palliative settings. To the best
of our knowledge, this is the first large survey to report
the effects of cancer treatment setting on tobacco use
assessment and barriers to provide support.
In curative setting patients, results are consistent with
the 2013 ASCO [15] and IASLC [16] surveys demon-
strating that about 90% of oncologists regularly ask
about tobacco use, 80e90% regularly advise patients to
quit smoking and 30e40% regularly provide assistance
to quit through medications or counselling. In contrast,
patients in the palliative setting received consistently
lower support with 54% advised to quit and 18e24%
provided medications or counselling. This unique
finding suggests that oncologists perceive tobacco
cessation as less important in the palliative setting,
particularly due to the reported hesitations from not
feeling comfortable taking something away patients
might enjoy doing, and less belief in an effect on out-
comes. To date, the evidence on survival benefits in
patients with stage IV disease is indeed sparse [17e21];
Table 3
Oncologist’s interactions with cancer patients.




Rarely Never N/A p-Value
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) C versus P
I ask patients if they smoke or use tobacco products C 361 (73%) 100 (20%) 22 (4%) 8 (2%) 2 (<1%) 3 (1%) <0.001
P 260 (51%) 136 (27%) 48 (10%) 41 (9%) 11 (2%) 0 (0%)
I ask patients if they use other tobacco products
such as cigars, pipes, snuff, hookah/shisha,
IQOS, etc.
C 183 (37%) 97 (20%) 84 (17%) 93 (19%) 35 (7%) 4 (1%) <0.001
P 136 (27%) 102 (21%) 83 (17%) 117 (24%) 55 (11%) 3 (1%)
I ask patients if they use electronic cigarettes or
other electronic nicotine delivery devices
C 132 (27%) 63 (13%) 65 (13%) 121 (24%) 108 (22%) 7 (1%) 0.02
P 100 (20%) 64 (13%) 70 (14%) 127 (26%) 130 (26%) 5 (1%)
When asking about tobacco use, I use a
structured questionnaire or other structured
method for asking questions
C 69 (14%) 43 (9%) 27 (5%) 61 (12%) 279 (56%) 17 (3%) 0.28
P 59 (12%) 38 (8%) 30 (6%) 61 (12%) 293 (59%) 15 (3%)
I ask patients who smoke or use tobacco if they
want to quit smoking
C 231 (47%) 139 (28%) 69 (14%) 32 (7%) 22 (4%) 3 (1%) <0.001
P 134 (27%) 113 (23%) 117 (24%) 84 (17%) 48 (10%) 0 (0%)
I advise patients who smoke or use tobacco
products to stop smoking
C 313 (63%) 123 (25%) 37 (8%) 14 (3%) 6 (1%) 3 (1%) <0.001
P 134 (27%) 135 (27%) 117 (24%) 75 (15%) 35 (7%) 0 (0%)
I discuss medication options such as nicotine
replacement, bupropion, varenicline, etc.
C 71 (14%) 122 (25%) 146 (29%) 102 (21%) 49 (10%) 6 (1%) <0.001
P 35 (7%) 84 (17%) 138 (28%) 149 (30%) 83 (17%) 7 (1%)
I actively treat or refer patients for a smoking/tobacco
cessation intervention
C 62 (13%) 93 (19%) 145 (29%) 121 (24%) 64 (13%) 11 (2%) <0.001
P 30 (6%) 60 (12%) 113 (23%) 160 (32%) 123 (25%) 10 (2%)
During follow-up appointments, I continue to assess
smoking behaviour in active smokers, and ask
patients that have quit whether they might
have relapsed back into tobacco use
C 118 (24%) 135 (27%) 113 (23%) 84 (17%) 33 (7%) 13 (3%) <0.001
P 50 (10%) 79 (16%) 139 (28%) 141 (28%) 78 (16%) 9 (2%)









Yes, I mostly discuss




No. (%) No. (%) No. (%) No. (%) C versus P
My interactions with patients regarding
smoking/tobacco use (above questions),
differ between tobacco-related and
nonetobacco-related cancers
C 343 (69%) 113 (23%) 8 (2%) 32 (7%) 1.00
P 288 (58%) 126 (25%) 18 (4%) 64 (13%)
C Z curative, P Z palliative.
a 9% missing, and descriptive statistics of complete cases are presented.
J.W.G. Derksen et al. / European Journal of Cancer 138 (2020) 99e108104however, the body of evidence is expected to grow in the
near future given the current focus on this topic.
Nevertheless, still 64% of oncologists disagreed that
cessation is a waste of time because of no impact on
outcomes.
In contrast to assessing and addressing tobacco use,
barriers to support appeared more consistent between
the curative and palliative settings. Analysis of the
IASLC survey demonstrated that significant predictive
barriers to providing medications or counselling were a
lack of time for counselling or referral, lack of available
resources and lack of training or experience [22]. Our
results show that these predictive barriers were
remarkably consistent according to cancer treatment
intent with 60% versus 55% for lack of time, 56% versus
53% for lack of resources and 65% versus 61% for lack
of training or experience for curative versus palliative
setting, respectively.
Further comparisons between the current survey and
the 2013 surveys [15,16] show that a lack of time and
adequate training were more frequently reportedcompared with 2013, whereas no reimbursement and
other financial reasons were less frequently reported.
The latter finding might be caused by the nationality of
the respondents, because financial health care policies
differ between the US and European countries. Our
results show a high percentage of oncologists reporting
inadequate training and that more training is needed to
better support patients, which suggests that oncologists
are receptive to additional training regarding smoking
cessation support.
Clinicians might feel that smoking cessation should
mainly be emphasised in patients with either early stage
or curable disease. However, a large review of the
literature showed that smoking increases mortality in
patients with both early and advanced or metastatic
cancer [1]. Moreover, the 2020 Surgeon General’s
Report demonstrated that smoking cessation after a
cancer diagnosis was associated with improved overall
survival [3]. Smoking cessation after a cancer diagnosis
has further shown to improve cancer-related survival,
risk of second primary cancer and quality of life
Table 4
Potential barriers to smoking/tobacco cessation support.







No. (%) No. (%) No. (%) No. (%) No. (%) C versus P
The inability to get patients to quit smoking/tobacco use C 80 (17%) 243 (52%) 83 (18%) 53 (11%) 7 (2%) 0.08
P 77 (17%) 205 (44%) 131 (28%) 47 (10%) 6 (1%)
My own hesitation; it feels like bothering the patient,
and I do not feel comfortable taking something
away they might enjoy doing
C 5 (1%) 57 (12%) 45 (10%) 238 (51%) 121 (26%) <0.001
P 35 (8%) 163 (35%) 88 (19%) 130 (28%) 50 (11%)
Waste of time; cessation after diagnosis does not
affect outcomes in cancer patients
C 2 (<1%) 12 (3%) 35 (8%) 236 (51%) 181 (39%) <0.001
P 8 (2%) 55 (12%) 103 (22%) 207 (44%) 93 (20%)
Lack of time for counselling or to set up a referral C 68 (15%) 208 (45%) 70 (15%) 89 (19%) 31 (7%) 0.67
P 68 (15%) 183 (39%) 111 (24%) 82 (18%) 22 (5%)
No or limited reimbursement (financial reasons) C 26 (6%) 74 (16%) 170 (37%) 129 (28%) 67 (14%) 1.00
P 28 (6%) 69 (15%) 174 (37%) 129 (28%) 66 (14%)
Patient’s resistance to a cessation treatment C 68 (15%) 255 (55%) 69 (15%) 62 (13%) 12 (3%) 0.40
P 75 (16%) 252 (54%) 83 (18%) 49 (11%) 7 (2%)
Lack of training or experience in cessation interventions C 57 (12%) 246 (53%) 89 (19%) 66 (14%) 8 (2%) 0.31
P 52 (11%) 234 (50%) 103 (22%) 69 (15%) 8 (2%)
Lack of available resources or referrals for
cessation interventions
C 73 (16%) 184 (40%) 85 (18%) 109 (23%) 15 (3%) 0.51
P 68 (15%) 173 (37%) 103 (22%) 107 (23%) 15 (3%)
Abbreviations: C Z curative, P Z palliative.
a 14% missing, and descriptive statistics of complete cases are presented.
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hibitors, a positive association between current or ever
smoking and treatment response has been demonstrated
with several possible immunological explanations for
this finding [33,34]. Interestingly, one study (KEY-
NOTE-024) indicated better treatment outcomes for
former smokers compared with current smokers, sug-
gesting that smoking cessation before and during
immunotherapy could be beneficial [35]. Future work
remains to clarify the relationship between smoking and
targeted cancer therapeutics.
An enhanced focus on smoking cessation at the time
of a cancer diagnosis may increase patients’ action to
quit. It has been shown that cancer patients have a
higher quit rate, compared with people without cancer
[36]. Hence, this highly opportune situationdoften
referred to as the ‘teachable moment’dshould be used
by health care professionals to introduce cessation
support [37]. In our survey, oncologists indicated that
next to the treating oncologist, the primary care physi-
cian and clinical support staff were the most suitable to
provide cessation support. We would like to argue that
there is a role for the treating oncologist to identify to-
bacco use, advise patients to quit and either provide
support to help patients quit or provide referral to
evidence-based tobacco treatment resources. Depending
on the clinical situation and resources, the treating
oncologist may refer the patient to the primary care
physician, a dedicated tobacco treatment clinician, a
phone-based tobacco treatment program such as a
quitline, or clinical support staff who have been trained
to deliver evidence-based treatment for tobacco
dependence.It has recently been shown that providing
comprehensive tobacco treatments including intensive
counselling and proactive pharmacologic management
in the oncologic setting can lead to sustained cessation
in almost half of patients with cancer who smoke [38].
In response to these study results, Fiore et al. [39]
stated that an effective cessation treatment for pa-
tients with cancer who smoke should become the
fourth pillardand an integral and essential compo-
nentdof comprehensive cancer care, and describe in
detail which steps are needed to promote imple-
mentation of smoking cessation treatment in cancer
care. Moreover, assessment of smoking status and
initiation of cessation support should no longer
depend on preferences of individual oncologists, but
should be automated in electronic health record sys-
tems and regulated at the hospital level. Smoking
cessation support might, for example, be used as a
hospital performance indicator. This approach fits
well in the current era in which there is an increased
focus on delivering the best oncologic care at the
lowest cost to assure an appropriate allocation of re-
sources in health care systems [40]. When new anti-
neoplastic agents are introduced, the efficacy, safety
and costs of treatment are currently the main con-
siderations [41]. Continued smoking is a factor that
contributes to potential failure of first-line treatment
and leads to significant incremental costs to the health
care system [2]. Hence, smoking behaviour should be
given more consideration, especially when considering
its highly modifiable nature.
The inevitable limitation of the current survey study
is the presence of selective response. As respondents
J.W.G. Derksen et al. / European Journal of Cancer 138 (2020) 99e108106are likely to be oncologists with a higher interest in the
role of lifestyle factors, such as smoking, the results
may be an optimistic representation of ‘true’ daily
practices and perceptions towards tobacco use and
cessation support. Although generalisability might be
affected by the low response rate (~9.1%), the obtained
response rate is in line with other international
lifestyle-related surveys in the oncology setting [15,42]
and results are highly congruent with prior published
surveys using similar or identical questions [15,16]. In
general, true practice patterns of oncologists are likely
to be worse than our results show, which only
strengthens our recommendations of implementing
routine smoking behaviour assessments in every pa-
tient with cancer and including evidence-based smok-
ing cessation support in the oncologic care path.
Another limitation is that, although quitting smoking
is relevant at any point in time, surgeons were not
included in our target population. Smoking cessation is
already receiving increasing attention as a part of
surgical prehabilitation programs to improve post-
surgical outcomes [43,44], whereas cessation support
was expected to be less implemented by oncologists. In
addition, this target population was also chosen based
on our focus on the palliative setting in which patients
are most often seen by oncologists. Nevertheless, sup-
porting patient in quitting smoking remains a multi-
disciplinary responsibility. Strengths of this study
include the large sample of oncologists and participa-
tion of 16 European countries, which underpins the
broad support for the obtained results. Lastly, the
specific distinction between the curative and palliative
settings allowed to study the current views towards
cessation support in both these settings and to make
comparisons between them.
To conclude, this study demonstrates that oncolo-
gists appear to address tobacco use more frequently in
the curative setting than in the palliative setting. Un-
fortunately, this study further suggests that practice
patterns remain relatively unchanged despite significant
advances in the evidence base that smoking negatively
affects cancer treatment outcomes. The dominant
barriers of lack of time, resources and education sug-
gest that addressing these issues may improve treat-
ment that supports tobacco cessation in both the
curative and palliative settings. Given the increasing
survival of cancer patients treated with palliative
intent, smoking cessation support will be of increasing
relevance to improve survivorship and quality of life.
We recommend that all cancer patients should be
screened for smoking status at diagnosis, and active
smokers should have access to evidence-based smoking
cessation support to improve cancer treatment out-
comes as well as improve outcomes for nonecancer-
related health conditions known to be improved with
smoking cessation.Funding
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